Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Background & Aims The Model for End-Stage Liver Disease (MELD) has been established
as a reliable indicator of short-term survival in patients with end-stage liver disease. The …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Background Nonalcoholic steatohepatitis (NASH) is a common disease that is associated
with increased morbidity and mortality, but treatment options are limited. The efficacy and …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …